Drug resistance in metastatic castration-resistant prostate cancer

@article{eruga2011DrugRI,
  title={Drug resistance in metastatic castration-resistant prostate cancer},
  author={B. {\vS}eruga and A. Oca{\~n}a and I. Tannock},
  journal={Nature Reviews Clinical Oncology},
  year={2011},
  volume={8},
  pages={12-23}
}
Docetaxel in combination with prednisone is the standard of care in men with symptomatic castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with CRPC do not benefit from docetaxel or other systemic therapy and those who do benefit invariably progress and die of (or with) prostate cancer. Resistance to chemotherapy in metastatic CRPC is a result of cellular mechanisms of drug resistance intrinsic to prostate cancer and general mechanisms common to different… Expand
Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
TLDR
The molecules associated with resistance, such as the molecular chaperones heat shock proteins and clusterin, and the cytokines interleukin-6 (IL-6) and the divergent member of the tumor growth factor family MIC-1 (macrophage inhibitory cytokine-1 also named GDF-15) are discussed, and their interest as blood-based markers to monitor docetaxel resistance. Expand
Chemotherapy-based treatment for castration-resistant prostate cancer.
  • B. Šeruga, I. Tannock
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
With the approval of less toxic hormonal agents in the setting of docetaxel-resistant mCRPC, clinicians will have an opportunity to balance benefits and harms of new agents in an individual patient and may be able to use different agents in sequence. Expand
Androgen Receptor Signaling in Castration Resistant Prostate Cancer
TLDR
The mechanisms through which the AR signaling axis promotes resistance to androgen-deprivation therapy and drives progression of castration resistant prostate cancer (CRPC) are reviewed. Expand
Overcoming docetaxel resistance in prostate cancer: a perspective review
  • C. Hwang
  • Medicine
  • Therapeutic advances in medical oncology
  • 2012
TLDR
Recent therapeutic advances in metastatic castrate-resistant prostate cancer as well as ongoing clinical trials are discussed, including several new drugs that are effective after docetaxel failure, dramatically changing the therapeutic landscape for these patients. Expand
Therapeutic Advances in Medical Oncology Review
    Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    TLDR
    The cell-based immunotherapy sipuleucel-T produces longer OS times in chemotherapy-naïve patients, whereas the androgen biosynthesis inhibitor abiraterone acetate results in longerOS times following docetaxel, envisioned that these agents will change the standard of care for patients with metastatic CRPC. Expand
    Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    TLDR
    Molecular alterations in tumor cells during ADT are described, which lead to deregulation of different signaling pathways and castration-resistance, and how they might interfere with the clinical outcome of different second-line therapeutics. Expand
    Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
    TLDR
    A concise overview of the clinical development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer is provided, translational research addressing enzalUTamide response vs resistance is described and novel potential treatment strategies in the enzyme-resistant setting are highlighted. Expand
    Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
    TLDR
    It is observed that both androgen receptor (AR) positive and AR-negative PCa cells differentiate into a NE phenotype upon treatment with Dovitinib, a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT. Expand
    Overcoming Drug Resistance and Treating Advanced Prostate Cancer
    TLDR
    This review will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa, and address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis. Expand
    ...
    1
    2
    3
    4
    5
    ...

    References

    SHOWING 1-10 OF 125 REFERENCES
    Survivin mediates resistance to antiandrogen therapy in prostate cancer
    TLDR
    The study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells, supporting a novel mechanism of resistance to antiandrogen therapy. Expand
    Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    TLDR
    A transcription-based AR signature can detect AR activity within individual prostate cancer specimens and has the potential to help individualize and improve care for patients with castrate-resistant prostate cancer. Expand
    Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    TLDR
    The entirety of phase II and III data evaluating chemotherapy agents in second-line prostate cancer (HRPC) is reviewed. Expand
    A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    TLDR
    Docetaxel/erlotinib can be delivered safely in elderly patients with AIPC and anti-cancer disease activity appears generally comparable to docetaxe when used as monotherapy. Expand
    Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    TLDR
    Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment. Expand
    Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    • Y. Ning, J. Gulley, +14 authors W. Dahut
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    TLDR
    The addition of bevacizumab and thalidomide to docetaxel is a highly active combination with manageable toxicities, and the estimated median survival is encouraging, given the generally poor prognosis of this patient population. Expand
    A phase II trial of lapatinib in hormone refractory prostate cancer
    TLDR
    Patients with rising PSA on androgen deprivation therapy who completed antiandrogen withdrawal, if previously on anti androgen, and have not received chemotherapy were eligible and were treated with lapatinib at an oral dose of 1500 mg daily. Expand
    Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
    • G. Gravis, F. Bladou, +7 authors P. Viens
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2008
    TLDR
    Efficacy was defined as a decrease or stabilization of prostate-specific antigen (PSA) without clinical progression, and clinical benefit was achieved in 40% of patients, demonstrating an improvement in clinical benefit. Expand
    Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
    TLDR
    Sunitinib malate demonstrated promising activity in metastatic CRPC progressing after prior docetaxel, and was evaluated in patients with progressing metastaticCRPC following prior docentaxel. Expand
    Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
    • D. Danila, M. Morris, +14 authors H. Scher
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    TLDR
    This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy, with encouraging antitumor activity in heavily pretreated CRPC patients. Expand
    ...
    1
    2
    3
    4
    5
    ...